ERG and neoplasm: Therefore, PRISM-SRM assays can be adapted to detect ERG protein in cells present in clinical specimens (e.g., tissue, post-DRE urine, and circulating tumor cells in blood), and cell-free ERG protein present in the blood sera, providing an opportunity for its use in the clinical setting for detection in prostate cancer patients, and define treatment strategies in accordance.